Today: 7 February 2026
Subscribe
Browse Category

EPA:ENX.PA News 21 December 2025 - 3 January 2026

Euronext stock holds near €128 into New Year’s Day closure — what’s next for ENX shares

Euronext stock holds near €128 into New Year’s Day closure — what’s next for ENX shares

NEW YORK, January 1, 2026, 08:31 ET — Market closed Shares in Euronext N.V. (ENX.PA) last closed at €128.00, up 0.08%, in the final session of 2025. Euronext The small move leaves the pan-European exchange operator starting 2026 with investors focused on what usually drives its fee pool: market activity. More volatility typically means more trading, and exchanges tend to collect more fees when investors transact more often. That sensitivity matters in January, when flows often reset after a holiday lull. Euronext’s cash and derivatives markets are closed on Thursday for New Year’s Day across its venues, and U.S. markets
1 January 2026
·
Euronext News and Forecast (Dec. 21, 2025): Consolidated Tape Momentum, Post‑Trade Expansion, and What Analysts Expect for ENX in 2026

Euronext News and Forecast (Dec. 21, 2025): Consolidated Tape Momentum, Post‑Trade Expansion, and What Analysts Expect for ENX in 2026

Euronext (ENX.PA) is having a very “market-structure” kind of month—the sort of news cycle that doesn’t scream in neon, but quietly decides how European capital markets work (and who gets paid) for years. As of Sunday, December 21, 2025, the pan-European exchange group is sitting at the intersection of three big themes investors keep circling back to: Below is a detailed, publication-ready roundup of the latest news, forecasts, and market analysis shaping the Euronext story right now. The week in Euronext: why December 2025 matters If you’re trying to “read” Euronext’s playbook, a simple translation helps: This week’s headlines line
21 December 2025
·

Stock Market Today

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
COPENHAGEN, February 7, 2026, 23:19 CET — Market closed. Novo Nordisk A/S Class B shares will be back in focus when trading resumes on Monday after telehealth firm Hims & Hers said it would stop offering access to a $49 compounded version of Novo’s Wegovy pill following U.S. regulatory warnings. Novo’s Copenhagen-listed shares ended Friday at 295.50 crowns, up 5.3%, according to Reuters market data. (Reuters) Why it matters now: the $49 offer put a fresh spotlight on how quickly cheaper, unapproved copies can spread in the fast-growing obesity-drug market — and how hard it may be for drugmakers to
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Go toTop